Status:
COMPLETED
Comparative Effectiveness of Acupuncture and Nonsteroidal Anti-inflammatory Drugs for the Management of Aromatase Inhibitor Induced Arthralgia Among Breast Cancer Survivors
Lead Sponsor:
China Medical University Hospital
Conditions:
Breast Cancer
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Hormone therapy is used to treat women with hormone receptor-positive breast cancer and aromatase inhibitor (AI) is administered after menopause. AI therapy has been proven to be effective in improvin...
Eligibility Criteria
Inclusion
- Women who were postmenopausal aged more than 20 years old.
- history of stage 0 to III hormone receptor-positive breast cancer, and currently taking a third-generation AI (anastrozole, letrozole, or exemestane) for at least 3 month.
- Those who reported pain and/or stiffness in one or more joints, which started or worsened after initiation of AI therapy had worst joint pain rated at least three or greater on a 0-10 numerical rating scale in the preceding week.
Exclusion
- any prior acupuncture use for AI-induced joint symptoms or acupuncture within 1 months before entry
- inflammatory, metabolic, or neuropathic arthropathies
- bone fracture/surgery of an afflicted extremity during the preceding 6 months
- allergy to NSAID
- current use of narcotics
- bleeding or coagulation disorders
- localized skin infections
- needle phobia
- intra-articular corticosteroid within 4 weeks preceding the study
- any severe chronic or uncontrolled comorbid disease
Key Trial Info
Start Date :
March 28 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04511832
Start Date
March 28 2018
End Date
December 31 2021
Last Update
July 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan